Form 8-K - Current report:
SEC Accession No. 0001493152-25-007732
Filing Date
2025-02-20
Accepted
2025-02-20 16:45:33
Documents
18
Period of Report
2025-02-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 56546
2 ex10-1.htm EX-10.1 312321
3 ex10-2.htm EX-10.2 44566
4 ex99-1.htm EX-99.1 32661
5 ex99-1_001.jpg GRAPHIC 6008
  Complete submission text file 0001493152-25-007732.txt   773748

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE asbp-20250213.xsd EX-101.SCH 3831
7 XBRL DEFINITION FILE asbp-20250213_def.xml EX-101.DEF 31714
8 XBRL LABEL FILE asbp-20250213_lab.xml EX-101.LAB 37864
9 XBRL PRESENTATION FILE asbp-20250213_pre.xml EX-101.PRE 28325
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 7374
Mailing Address 1200 BROADWAY, FLOOR 3 NEW YORK NY 10038
Business Address 1200 BROADWAY, FLOOR 3 NEW YORK NY 10038 561-704-8527
Aspire Biopharma Holdings, Inc. (Filer) CIK: 0001847345 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41293 | Film No.: 25646130
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)